51285-26-8Relevant articles and documents
A Mitochondria-Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia
Lv, Wen,Zhang, Zhang,Zhang, Kenneth Yin,Yang, Huiran,Liu, Shujuan,Xu, Aqiang,Guo, Song,Zhao, Qiang,Huang, Wei
, p. 9947 - 9951 (2016)
Organelle-targeted photosensitizers have been reported to be effective photodynamic therapy (PDT) agents. In this work, we designed and synthesized two iridium(III) complexes that specifically stain the mitochondria and lysosomes of living cells, respectively. Both complexes exhibited long-lived phosphorescence, which is sensitive to oxygen quenching. The photocytotoxicity of the complexes was evaluated under normoxic and hypoxic conditions. The results showed that HeLa cells treated with the mitochondria-targeted complex maintained a slower respiration rate, leading to a higher intracellular oxygen level under hypoxia. As a result, this complex exhibited an improved PDT effect compared to the lysosome-targeted complex, especially under hypoxia conditions, suggestive of a higher practicable potential of mitochondria-targeted PDT agents in cancer therapy.
Substituted 2,4-Di(pyridin-2-yl)pyrimidine-Based Ruthenium Photosensitizers for Hydrogen Photoevolution under Red Light
Rupp, Mira T.,Auvray, Thomas,Shevchenko, Natali,Swoboda, Lukas,Hanan, Garry S.,Kurth, Dirk G.
, p. 292 - 302 (2021/01/11)
The photocatalytic reduction of water to form hydrogen gas (H2) is a promising approach to collect, convert, and store solar energy. Typically, ruthenium tris(bipyridine) and its many derivatives are used as photosensitizers (PSs) in a variety of photocatalytic conditions. The bis(terpyridine) analogues, however, have only recently gained attention for this application because of their poor photophysical properties. Yet, by the introduction of electron-donating or -withdrawing groups on the terpyridine ligands, the photophysical and electrochemical properties can be considerably improved. In this study, we report a series of nonsymmetric 2,6-di(pyridin-2-yl)pyrimidine ligands with peripheral pyridine substituents in different positions and their corresponding ruthenium(II) complexes. The presence of the pyrimidine ring stabilizes the lowest unoccupied molecular orbital, leading to a red-shifted emission and prolonged excited-state lifetimes as well as higher luminescence quantum yields compared to analogous terpyridine complexes. Furthermore, all complexes are easier to reduce than the previously reported bis(terpyridine) complexes used as PSs. Interestingly, the pyridine substituent in the 4-pyrimidine position has a greater impact on both the photophysical and electrochemical properties. This correlation between the substitution pattern and properties of the complexes is further investigated by using time-dependent density functional theory. In hydrogen evolution experiments under blue- and red-light irradiation, all investigated complexes exhibit much higher activity compared to the previously reported ruthenium(II) bis(terpyridine) complexes, but none of the complexes are as stable as the literature compounds, presumably because of an additional decomposition pathway of the reduced PS competing with electron transfer from the reduced PS to the catalyst.
A gas-phase study on the cyclometallation of a series of Cp*Ir(III) complexes bearing bidentate pyrimidine ligands
Becker, Yanik,Huber, Maximilian,Becker, Sabine,Sun, Yu,Niedner-Schatteburg, Gereon,Thiel, Werner R.
, (2021/09/20)
A concerted approach of synthesis and gas phase experiments characterizes the relative cyclometallation barriers of a series of cationic η5-Cp* iridium(III) compounds. The common feature of the investigated compounds is a bidentate N,N’-donor ligand possessing a pyridine site functionalized with a 5-butylpyrimidin-2-yl ring in the 2-position. In addition, the pyridine ring was functionalized with electron-donating or -withdrawing groups. The compounds were characterized by means of NMR and IR spectroscopy and elemental analysis. For the measurements of the relative barriers of the cyclometallation, collision-induced dissociation (CID) experiments were carried out, which revealed a clear dependence of the relative barriers from the nature and the position of the substituents at the pyridine ring could be worked out.
Preparation method and application of phosphorescence iridium complexes with mitochondrial targeting function
-
Paragraph 0026-0028, (2017/02/23)
The invention discloses phosphorescence iridium complexes with a mitochondrial targeting function, and a preparation method thereof, and an application thereof in biological imaging and oxygen detection. The complexes are composed of a cyclic metal ligand, a metal center and an auxiliary ligand containing a mitochondrial targeting function group, and the structure of the complexes is represented by a general formula shown in the description; the luminous intensity and the emission life of the complexes reduce with the increase of the oxygen concentration; mitochondria of living cells are marked; the change of the concentration of oxygen in the mitochondria of living cells is detected through a confocal imaging and life imaging technology; and the phosphorescence iridium complexes have important application prospect in biological imaging and sensing fields.
The phosphorescence of the response characteristic of a complex, and its preparation method and application
-
Paragraph 0032-0035, (2017/04/29)
The invention relates to a phosphorescent iridium complex with stimuli responsibility. The phosphorescent iridium complex is composed of a cyclometalated ligand, a metal center and an assistant ligand containing an active function group, and has the structure general formula shown in the specification. The compound disclosed by the invention is capable of causing variation of phosphorescence emission wavelength under stimulation of an acidic or basic reagent; also under electricity stimulation, the compound is capable of causing variation of emission wavelength and also is capable of causing variation of emission lifetime; and based on the electricity stimulation response characteristics and by means of time resolution technology, the phosphorescent iridium complex is applicable to construct memory devices for information recording, encryption and decryption. The phosphorescent iridium complex disclosed by the invention has important application prospect on aspects of information recording, information encryption and the like.
Blue-emitting Ir(III) complexes using fluorinated bipyridyl as main ligand and 1,2,4-triazol as ancillary ligand: syntheses, photophysical properties and performances in devices
Sun, Peng,Wang, Kexiang,Zhao, Bo,Yang, Tingting,Xu, Huixia,Miao, Yanqin,Wang, Hua,Xu, Bingshe
supporting information, p. 8335 - 8341 (2016/12/02)
The blue-light-emitting Ir(III) complexes using 2-(3-(trifluoromethyl) -1H-1,2,4-triazol-5-yl)pyridine and fluorinated 2-phenylpyridine as ligands were synthesized and characterized in details. Their molecular structures were confirmed by1H NMR
METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS
-
Paragraph 0237; 0238; 0239; 0240, (2016/10/08)
The present invention relates inter alia to a new class of heteroleptic metal complexes comprising condensed aromatic heterocyclic rings, their preparation and use.
Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1
Zhang, Pengtao,Yang, Xinye,Zhang, Feiran,Gabelli, Sandra B.,Wang, Renxiao,Zhang, Yihua,Bhat, Shridhar,Chen, Xiaochun,Furlani, Manuel,Amzel, L. Mario,Liu, Jun O.,Ma, Dawei
, p. 2600 - 2617 (2013/06/27)
Cellular protein synthesis is initiated with methionine in eukaryotes with few exceptions. Methionine aminopeptidases (MetAPs) which catalyze the process of N-terminal methionine excision are essential for all organisms. In mammals, type 2 MetAP (MetAP2)
SUBSTITUTED PYRIMIDINES
-
Page/Page column 33; 102; 103, (2013/04/10)
Disclosed are substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
SUBSTITUTED PYRIMIDINES
-
Page/Page column 32; 33; 102; 103, (2013/04/10)
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
